---
title: Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
nct_id: NCT00004938
overall_status: COMPLETED
phase: PHASE2
sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
study_type: INTERVENTIONAL
primary_condition: Sporotrichosis
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00004938.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00004938"
ct_last_update_post_date: 2006-06-09
last_seen_at: "2026-05-12T07:30:55.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis

**NCT ID:** [NCT00004938](https://clinicaltrials.gov/study/NCT00004938)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Collaborators:** University of Alabama at Birmingham
- **Conditions:** Sporotrichosis
- **Start Date:** 1996-08
- **Completion Date:** 1996-08
- **CT.gov Last Update:** 2006-06-09

## Brief Summary

OBJECTIVE:

I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.

## Detailed Description

PROTOCOL OUTLINE:

Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year.

## Eligibility

- **Minimum age:** 12 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Presumptive evidence of sporotrichosis Culture-proven sporotrichosis determined on study Relapsing disease following antifungal therapy eligible if culture positive for Sporothrix schenckii prior to entry No life-threatening disease No central nervous system sporotrichosis --Prior/Concurrent Therapy-- No concurrent drugs known to react with fluconazole No more than 3 days of systemic antifungals for current sporotrichosis episode --Patient Characteristics-- Hepatic: Liver function tests no greater than 5 times normal Other: No HIV infection No pregnant or nursing women
```

## Interventions

- **fluconazole** (DRUG)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00004938.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00004938*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*